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Dear eDitor:
In most cases, bladder carcinoma is located superficially, 
and the therapeutic approach is usually transurethral 
resection followed by intravesical therapy (chemotherapy or 
immunotherapy).(1,2) Initially produced as a vaccine against 
tuberculosis, BCG—an attenuated strain of Mycobacterium 
bovis—has been widely used in immunotherapy over the 
last decades.(1,3) Although BCG, used as immunotherapy, 
has not produced the best results in many cancers, it has 
been clinically successful in the intravesical treatment of 
superficial bladder carcinomas.(4) Immunotherapy with 
intravesical BCG eradicates the residual tumor, slows 
the progression of the disease, reduces the need for 
cystectomy, and prolongs survival.(4) Treatment with 
BCG is well tolerated by over 95% of patients. The most 
common side effects are local (inflammation, fever, and 
pelvic adenopathy). However, although rare, systemic 
complications have been described.(1,3-6) Systemic dissem-
ination of the attenuated M. bovis bacillus is known as 
BCGitis. It is more common in individuals with underlying 
primary or secondary immunodeficiency but can occur in 
immunocompetent patients.(1,6) There have been only a 
few reports of cases of respiratory BCGitis.(1,2,6) Here, we 
report the case of a patient who was treated with local 
BCG immunotherapy for urothelial bladder carcinoma 
and developed a severe M. bovis respiratory infection.
In March of 2013, a 72-year-old male presented 
with hematuria. The patient also had hypertension, 
dyslipidemia, cerebrovascular disease (previous stroke), 
chronic renal failure, and depression. He was being treated 
with perindopril, indapamide, atorvastatin, acetylsalicylic 
acid, furosemide, and escitalopram. He had no known 
drug allergies. Ultrasound revealed a 2.5-cm polyp in the 
bladder. The patient underwent transurethral resection 
of the bladder tumor. Histological examination revealed 
urothelial cell carcinoma (grade 2), without vascular or 
muscle invasion. Chemotherapy and immunotherapy 
with intravesical instillation of BCG were started and 
continued until December of 2013. In February of 2014, 
the patient presented to the emergency department with 
a one-week history of dyspnea and productive cough 
(mucopurulent sputum). He reported no fever, chest 
pain, hemoptysis, sweating, or other symptoms. On 
physical examination, he was afebrile, with an increased 
respiratory rate, hemodynamic stability, and an SpO2 of 
89% on room air. Auscultation revealed bilateral breath 
sounds, with crackles in both lung bases. There were 
no other significant changes. Ancillary tests showed a 
C-reactive protein level of 10 mg/dL, without leukocy-
tosis, together with normal liver and kidney function, 
overlapping with previous studies of the patient. Blood 
gas analysis (at a FiO2 of 24%) showed a pH of 7.43, a 
PaO2 of 66 mmHg, a PaCO2 of 45 mmHg, and an HCO3 of 
29.9 mEq/L. In addition, a chest X-ray showed bilateral 
diffuse reticulonodular infiltrates. A CT scan of the chest 
revealed randomly distributed micronodules in the lungs, 
together with enlargement of the hilar and mediastinal 
lymph nodes (Figure 1). After having collected sputum 
for analysis, we started empirical antibiotic treatment 
with amoxicillin and clavulanic acid. Due to respiratory 
failure and suspected miliary tuberculosis or diffuse 
pulmonary metastasis, the patient was admitted to the 
respiratory ward of the hospital. 
During hospitalization, microbiological and mycobac-
teriological cultures of sputum samples were negative. 
Bronchoscopy revealed bilateral mucopurulent secretions, 
edema, and diffuse mucosal congestion. Microbiological 
cultures of bronchial lavage and BAL fluid (BALF) samples 
were negative. Although the BALF was negative for M. 
tuberculosis on smear microscopy, it tested positive for 
M. tuberculosis complex DNA and for M. bovis in cultures. 
Cytology of the BALF was negative for malignant cells; 
the patient also tested negative for the viral markers 
Figure 1. Chest CT scan showing randomly distributed micronodules in the lungs, together with enlargement of the hilar 
and mediastinal lymph nodes.
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of infection with HIV, HCV, and HBV. Because of the 
positive result on the nucleic acid amplification test 
of the BALF, we started tuberculosis treatment with 
isoniazid, rifampin, pyrazinamide, and ethambutol. 
Despite improvements in his test results and clinical 
resolution of the respiratory failure, the patient showed 
a slight increase in liver enzymes (to less than double 
the normal values). He underwent upper abdominal 
ultrasound, which revealed hepatic steatosis with no 
other abnormalities. In view of the BALF culture positivity 
for M. bovis (which is naturally pyrazinamide-resistant), 
we suspended the pyrazinamide, and the liver enzyme 
values normalized thereafter. 
The patient was discharged and continued treatment 
on an outpatient basis. Future scheduled BCG instillations 
were suspended. In the initial phase of treatment, 
the regimen was the isoniazid-rifampin-ethambutol 
combination, whereas the isoniazid-rifampin combination 
was used in the maintenance phase. After a total of 
6 months of treatment, the patient showed a good 
response. At this writing, the patient remains under 
follow-up monitoring of his bladder, without signs of 
recurrence. The patient gave written informed consent 
for the reporting of his case.
Various recent studies have analyzed the outcomes 
of patients with bladder carcinoma who underwent 
therapeutic intravesical instillation of BCG. The study 
conducted by Lamm et al. showed that disseminated 
BCGitis was extremely rare.(2) Some studies have 
reported that, among patients with bladder cancer, 
there is a relationship between the complications of 
BCG instillation and a prior diagnosis of tuberculosis, 
such complications not occurring in patients without a 
history of tuberculosis and with no evidence of sequelae 
on chest X-rays.(1)
In this report, we have presented the case of a male 
patient without a history of tuberculosis who developed 
a respiratory infection soon after treatment with 
intravesical instillation of BCG. The initial diagnostic 
hypotheses included malignancy. However, after careful 
investigation, the patient was diagnosed with BCGitis, 
with no remaining doubt that the lung disease was 
due to the spread of the BCG used in the treatment 
of his bladder carcinoma. Despite the rarity of this 
complication, our case report underscores the need 
for vigilance and awareness of the possibility of BCG 
dissemination, given the widespread use of BCG in 
patients with bladder carcinoma.
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